echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > BJU Int: Feasibility and safety assessment of radical prostatectomy for oligometastatic prostate cancer

    BJU Int: Feasibility and safety assessment of radical prostatectomy for oligometastatic prostate cancer

    • Last Update: 2022-02-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Prostate cancer is the most common cancer in Western men and the second leading cause of cancer death
    .
    Median survival for patients with metastatic disease was 42.


    1 months, and until recently the standard of care was the original androgen deprivation therapy (ADT)


    Until recently, the standard of care was also the original androgen deprivation therapy (ADT) until recently, the standard of care was also the original androgen deprivation therapy (ADT) only

    Recently, researchers from the United Kingdom published an article in "BJU Int" to test the randomization of radical prostatectomy plus pelvic surgery on the basis of standard of care (SOC) systemic treatment in men with newly diagnosed oligometastatic prostate cancer.
    Feasibility of lymphadenectomy (RP)
    .

    Diagnostically tested the feasibility of randomization to radical prostatectomy plus pelvic lymphadenectomy (RP) on the basis of standard of care (SOC) systemic therapy Feasibility tested randomization to radical prostatectomy on the basis of standard of care (SOC) systemic therapy Feasibility of plus pelvic lymphadenectomy (RP)

    The study was a prospective, randomized, open-label, feasibility clinical trial using the QuinteT Recruitment Intervention (QRI) to optimize recruitment and was conducted in nine tertiary care centers across the country
    .
    During an 18-month recruitment period, 50 men with oligometastatic prostate cancer were randomized to SOC systemic therapy versus SOC plus RP (intervention group)


    .


    Quality of Life

    RESULTS: Of the 176 participants, a total of 71 met the inclusion criteria, of whom 51 men were randomized (one of whom was subsequently determined to be ineligible)
    .
    Under QRI-optimized conditions, recruitment increases were 60-83%


    .


    PSA, function, and quality of life outcomes 3 months after randomization

    PSA, function, and quality of life outcomes 3 months after randomization

    In conclusion, random surgical intervention in men with synchronous oligometastatic prostate cancer is feasible in addition to standard systemic therapy
    .
    Although in this feasibility study the surgery appeared to be safe with no substantial impact on QOL , a large randomized controlled trial is warranted to test this multimodal management of other oligometastatic prostate cancer Treatment effects of interventions


    .


    Randomized surgical intervention in men with synchronous oligometastatic prostate cancer is feasible in addition to standard systemic therapy


    Original source:

    Prasanna Sooriakumaran, Caroline Wilson, Ines Rombach et al.


    Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: TRoMbone trial .


    Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: TRoMbone trial Leave a Comment
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.